| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_08e00d6c0f225b2092510b9d4c97635d |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55555
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-70 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-25
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-295
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-19 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-19
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-25
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-295
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-39 |
| filingDate |
2017-08-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d0be3d52ae87ed51c14bea9aa1afcc6c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c47cc070d8d121746c2e6747d2466a59
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1b6a1c4f424b62c41c968557608c8e91
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2bbd8ba658b91b20e0b55355ea011db6 |
| publicationDate |
2019-03-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20190021939-A |
| titleOfInvention |
Varicella-zoster virus vaccine composition comprising cationic liposome and use thereof |
| abstract |
The present invention relates to a varicella zoster virus vaccine composition comprising a cationic liposome and a use thereof. The present invention relates to a lipopolysaccharide (LPS) analogue and a cationic liposome And to uses thereof. ≪ Desc / Clms Page number 2 > The present invention overcomes the physicochemical instability of liposomes and is advantageous not only in production, transportation and storage, but also as an immune delivery system by improving stability. In addition, the present invention includes both an immune response modulating substance and a cationic liposome, thereby exhibiting an enhanced immune enhancing effect as compared with the case of using an immune response modulating substance alone. In addition, the present invention can be manufactured in a ready-to-use form since all the components contained in the vaccine composition are contained in one container, which is more convenient to use. |
| priorityDate |
2017-08-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |